home / stock / gnmsf / gnmsf message board
Subject | By | Source | When |
---|---|---|---|
Products in development | XenaLives | investorshub | 10/27/2019 2:32:31 PM |
Product pipeline | XenaLives | investorshub | 10/27/2019 2:32:00 PM |
About Genmab A/S | XenaLives | investorshub | 10/27/2019 2:25:49 PM |
$GMXAY largest holding in Blackrock fund: | XenaLives | investorshub | 10/27/2019 2:23:21 PM |
Genmab Announces Phase II Study of Daratumumab in | PennyStock Alert | investorshub | 09/16/2019 12:43:50 PM |
GMXAY Forward Split 5 for 1 effective May | TenKay | investorshub | 04/17/2018 2:17:06 AM |
Here are Two Biotech Stocks to Watch in | trendmkr | investorshub | 12/31/2015 11:04:54 PM |
$GMXAY DD Notes ~ http://www.ddnotesmaker.com/$GMXAY | stocktrademan | investorshub | 12/04/2014 7:43:31 PM |
Genmab has taken a beating along with a | akademikeren | investorshub | 04/15/2014 9:55:50 AM |
Stock Tracker: Latest Genmab A/S Dkk (GNMSF) Headlines Genmab Announces Phase III Study of Daratumum | Stock_Tracker | investorshangout | 03/10/2014 4:46:26 AM |
chartguy89: GNMSF 46.72 Stock Charts $GNMSF 1 Month Chart | chartguy89 | investorshangout | 03/07/2014 6:03:52 PM |
chartguy89: GNMSF Stock Charts Last: -0.30 Wednesday, February 26, 2014 at 1:11:32 PM $GNMSF | chartguy89 | investorshangout | 02/26/2014 6:11:43 PM |
News, Short Squeeze, Breakout and More Instantly...
Company Announcement Positive CHMP opinion based on results from the Phase 1/2 EPCORE ® NHL-1 study FL is the second most common type of NHL and accounts for approximately 20-30 percent of all global cases If approved, epcoritamab (TEPKINLY ® ...
Company Announcement Genmab has completed acquisition of ProfoundBio for USD 1.8 billion in cash Acquisition gives Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan (Rina-S), plus ProfoundBio’s novel antibody-drug conjugat...
May 2, 2024 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2024 Highlights The U.S. Food and Drug Administration (U.S. FDA) granted Priority Review for the supplemental Biologics License Application (sBLA) for EPKINLY ® (epcorita...